Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Study Details
Study Description
Brief Summary
This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Phase 1/Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- To assess the safety of dabrafenib mesylate (dabrafenib) in combination with uprosertib (GSK2141795) and select the optimal dose of GSK2141795 for the phase II portion in patients with BRAF mutant cancer. (Effective November 15, 2014, this trial will not proceed to the Phase II study of dabrafenib and GSK2141795, but will move to an evaluation of triple therapy). (Phase I) II. To assess the safety of dabrafenib and trametinib dimethyl sulfoxide (trametinib) and GSK2141795 in combination and select the optimal dose of the combination for the Phase II Portion in patients with BRAF mutant cancer. (Phase I) III. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial responses) in patients with BRAFV600 mutant metastatic melanoma who have previously progressed on BRAFV600 inhibitor-based therapy (BRAFi), or BRAFi + MEK inhibitor-based therapy (MEKi). (Phase II)
SECONDARY OBJECTIVES:
- To estimate overall survival and progression-free survival. II. To assess the toxicity profile of the recommended phase II dose. III. To assess response (complete and partial, confirmed and unconfirmed) of patients enrolled on each phase I portion).
TRANSLATIONAL MEDICINE OBJECTIVES:
-
To explore the molecular mechanisms of acquired resistance to BRAF inhibitor therapy using available biopsies of lesions that progressed during prior BRAF inhibitor-based therapy.
-
To explore potential drug-drug interactions between dabrafenib and GSK2141795 leading to changes in the expected exposure with either agent compared to prior experience. (Phase I)
OUTLINE: This is a phase I, dose-escalation study of uprosertib followed by a phase II study. Dose escalation of dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib will be initiated after completion of the dabrafenib + uprosertib phase I dose escalation.
Dabrafenib mesylate and uprosertib: Patients receive dabrafenib orally (PO) twice daily (BID) and uprosertib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib: Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 2 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (uprosertib, dabrafenib, trametinib) Dabrafenib mesylate and uprosertib: Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib: Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Drug: Dabrafenib Mesylate
Given PO
Other Names:
Drug: Trametinib Dimethyl Sulfoxide
Given PO
Other Names:
Drug: Uprosertib
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib. [Every 2 weeks during days 1-56 of treatment.]
MTD was evaluated by testing increasing doses up to 75 mg once a day, given in combination with dabrafenib dosed at 150 mg twice daily. MTD reflects the highest dose that did not cause a DLT. DLTs were defined as treatment regimen related: febrile neutropenia; Grade 4 neutropenia lasting more than 7 days; Grade 4 platelet count decrease; Grade 3-4 rash, fever, or hyperglycemia > 14 days, e) Grade 3-4 non-hematologic adverse events lasting greater than 7 days. Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
- Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib. [Every 2 weeks during days 1-56 of treatment.]
MTD was evaluated by testing increasing doses up to 75 mg once a day, given in combination with dabrafenib dosed at 150 mg twice daily and trametinib at either 1.5 mg or 2 mg once a day. MTD reflects the highest dose that did not cause a dose-limiting toxicity (DLT). DLTs were defined as treatment regimen related: febrile neutropenia; Grade 4 neutropenia lasting more than 7 days; Grade 4 platelet count decrease; Grade 3-4 rash, fever, or hyperglycemia > 14 days, e) Grade 3-4 non-hematologic adverse events lasting greater than 7 days. Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Note: MTD for the triplet regimen could not be determined due to the end of supply of the study drug. Number reported is the maximum dose of GSK2141795 that was assessed in combination with 150 mg Dabrafenib and 2 mg trametinib.
- Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses) as Assessed by RECIST Version 1.1 of the Doublet Regimen GSK2141795 + Dabrafenib at the Phase I Determined MTD. (Phase II) [Disease assessments every 8 weeks for up to 3 years]
All measurable lesions up to a maximum of 2 lesions per organ 5 lesions in total, representative of all involved organs, were identified as target lesions at baseline. All other lesions (or sites of disease) were identified as non-target lesions. Complete Response (CR): Complete disappearance of all target and nontarget lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to < 1.0 cm. Partial Response (PR): <= 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Unconfirmed CR: One objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR: One objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.
- Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses) as Assessed by RECIST Version 1.1 of the Triplet Regimen GSK2141795 + Dabrafenib + Trametinib at the Phase I Determined MTD. (Phase II) [Disease assessments every 8 weeks for up to 3 years]
All measurable lesions up to a maximum of 2 lesions per organ 5 lesions in total, representative of all involved organs, were identified as target lesions at baseline. All other lesions (or sites of disease) were identified as non-target lesions. Complete Response (CR): Complete disappearance of all target and nontarget lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to < 1.0 cm. Partial Response (PR): <= 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Unconfirmed CR: One objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR: One objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.
Secondary Outcome Measures
- Overall Survival (Phase II) of Patients Treated at the Phase I Determined MTD of Doublet Regimen [From date of registration to date of death due to any cause, assessed up to 3 years]
Estimated with 95% confidence interval.
- Overall Survival (Phase II) of Patients Treated at the Phase I Determined MTD of Triplet Regimen [From date of registration to date of death due to any cause, assessed up to 3 years]
Estimated with 95% confidence interval.
- Progression-free Survival as Assessed by RECIST Version 1.1 of the Doublet Regimen at the Phase I Determined MTD (Phase II) [From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years]
Estimated with 95% confidence interval.
- Progression-free Survival as Assessed by RECIST Version 1.1 of the Triplet Regimen at the Phase I Determined MTD (Phase II) [From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years]
Estimated with 95% confidence interval.
- Toxicity Rate of MTD Graded by the NCI CTCAE Version 4.0 (Phase II) [Up to 3 years]
Other Outcome Measures
- Pharmacokinetic Parameters [Baseline, pre-dose and 1, 2, 4, and 8 hours on day 15, and pre-dose day 29]
- Prevalence of Markers [Up to 3 years]
For binary markers, the prevalence will be able to be estimated and exact binomial confidence interval will be calculated. The association between these categorical markers and clinical outcomes will be explored in a preliminary manner, using Fisher's exact test to compare response and a logrank test to compare Kaplan-Meier estimates of overall survival and progression free survival between marker positive and marker negative groups.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
PHASE I PORTION ELIGIBILITY CRITERIA
-
Patients must have BRAFV600 mutant metastatic cancer irrespective of the histology or prior therapy; BRAFV600 mutant status must be documented by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; use of an Food and Drug Administration (FDA)-approved test is preferred although other BRAF tests at a CLIA-certified laboratory may also be accepted
-
Patients must have locally advanced unresectable stage IIIC or metastatic stage IV cancer with either progression to prior therapy or a newly diagnosed cancer that does not have an available treatment with curative intent
-
Patients must have a complete physical examination and medical history within 28 days prior to registration
-
Patients must have measurable or non-measurable disease; all measurable lesions must be assessed (by physical examination, computed tomography [CT], or magnetic resonance imaging [MRI] scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
-
All patients must undergo a CT or MRI of the brain within 42 days prior to registration; patients with asymptomatic brain metastases or previously treated brain metastases that are stable (i.e. not requiring corticosteroids) at the time of registration will be eligible
-
Patients may have received prior systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination regimens); all adverse events associated with prior treatment must have resolved to < grade 1 prior to registration
-
Patients progressing on a prior BRAF inhibitor-based therapy will be eligible, as are patients naive to BRAF inhibitor therapy; resistance to BRAF inhibitor-based therapy will be defined as progressive disease by RECIST 1.1 criteria while receiving therapy with a BRAF inhibitor (vemurafenib or dabrafenib, alone or in combination with a mitogen-activated protein kinase [MEK] inhibitor); this may be innate resistance (patients who never achieved a tumor response while on BRAF inhibitor therapy) or acquired resistance (progression after having a tumor response to BRAF inhibitor therapy); there will not be a period of break between progression on the prior BRAF inhibitor-based therapy and the start of dabrafenib, trametinib and GSK2141795
-
Patients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade 1 prior to registration
-
Patients may have received prior radiation therapy; all adverse events associated with prior radiation therapy must have resolved to =< grade 1 prior to registration
-
Patients must be willing to submit blood for pharmacokinetics; sites must order S1221 pharmacokinetic (PK) kit immediately after registration; the Southwest Oncology Group (SWOG) patient identification (ID) number must be provided on the S1221 PK Kit request form
-
Patients must have available and be willing to submit baseline tissue taken at the time of disease progression to prior BRAF inhibitor-based therapy (either fresh frozen [preferred], or paraffin-embedded tumor blocks) OR must have a site of disease that can be biopsied within this study for translational medicine studies; tissue may be from an archival biopsy or a new biopsy after the patient has been registered to the protocol; since patients are referred to this protocol after progression on prior BRAF inhibitor-based therapy, the biopsy taken at the time of progression will be used as the baseline biopsy for this study; patients must be willing to submit plasma and whole blood for translational medicine studies
-
Patients must have Zubrod performance status =< 1
-
Absolute neutrophil count (ANC) >= 1,200/ul (obtained within 28 days prior to registration)
-
Platelets >= 100,000/ul (obtained within 28 days prior to registration)
-
Hemoglobin >= 9 g/dL (obtained within 28 days prior to registration)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 2.5 x ULN for patients with Gilbert's syndrome) (with 28 days prior to registration)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases) (obtained within 28 days prior to registration)
-
Serum albumin >= 2.5 g/dL (obtained within 28 days prior to registration)
-
Serum creatinine =< 1.5 mg/dL OR measured or calculated creatinine clearance >= 50 mL/min (obtained within 28 days prior to registration)
-
Patient must have a left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA) within 28 days prior to registration
-
Patients with melanoma must have a serum lactate dehydrogenase (LDH) test performed within 28 days prior to registration
-
Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)
-
Patients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic range
-
Women of childbearing potential must have a negative pregnancy test within 14 days of registration
-
Patients must be able to retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels; patients who have feeding tubes can enroll in the study provided that the capsules do not need to be modified
-
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
-
Patients must have a serum albumin >= 2.5 g/dL within 28 days prior to registration
-
PHASE II PORTION ELIGIBILITY CRITERIA
-
Patients must have histologically confirmed melanoma with BRAF^V600 mutation; patients must have stage IIIC or stage IV disease
-
Patients must have received prior BRAF inhibitor therapy (e.g. dabrafenib, vemurafenib) within 56 days prior to registration; prior trametinib therapy is permitted; patients are not required to interrupt BRAF or MEK inhibitor therapy prior to the initiation of three agent combination therapy on study
-
Patients must have measurable disease; all measurable lesions must be assessed (by physical examination, CT, or MRI scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
-
Patients must have Zubrod performance status =< 2
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years; patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study; Note: Prospective RAS testing is not required; however, if the results of previous RAS testing are known, they must be used in assessing eligibility
Exclusion Criteria:
-
Patients must not have a corrected QT (QTc) interval >= 480 msecs within 28 days prior to registration
-
At the time of registration, patients must not be receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8); patients must not be planning to use herbal remedies (e.g., St. John's wort), or strong inhibitors or inducers of P-glycoprotein (Pgp) or breast cancer resistance protein 1 (Bcrp1)
-
Patients must not have a history of acute coronary syndromes (including unstable angina), myocardial infarction within 6 months, coronary angioplasty, or stenting within the past 24 weeks; class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; or history of known cardiac arrhythmias (such as atrial fibrillation) unless it has been stably controlled for > 30 days prior to registration; abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis]) can be entered on study; subjects with moderate valvular thickening are not eligible
-
Patients must not be pregnant or nursing due to unknown teratogenic side effects; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; hormonal contraception is not allowed due to drug interactions which can render hormonal contraceptives ineffective; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
-
Patient must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, previously diagnosed type 1 diabetes mellitus/type 2 diabetes, psychiatric illness/social situations, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements; patients must not have any evidence of mucosal or internal bleeding; patients must not have a history of pneumonitis or interstitial lung disease; patients must not have received any major surgery within four weeks prior to registration
-
Patients must not have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
-
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)
-
Patients with known history or current evidence of retinal vein occlusion (RVO) are not eligible:
-
History of RVO, or predisposing factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)
-
Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO such as:
-
Evidence of new optic disc cupping
-
Evidence of new visual field defects
-
Intraocular pressure > 21 mmHg
-
NOTE: Ophthalmic exam is required for all patients; exam must be obtained within 28 days prior to registration
-
Patients must not have uncontrolled hypertension (defined as systolic blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg which cannot be controlled by anti-hypertensive therapy)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | USC / Norris Comprehensive Cancer Center | Los Angeles | California | United States | 90033 |
| 2 | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | United States | 90095 |
| 3 | California Pacific Medical Center-Pacific Campus | San Francisco | California | United States | 94115 |
| 4 | UCSF Medical Center-Mount Zion | San Francisco | California | United States | 94115 |
| 5 | University of Colorado Hospital | Aurora | Colorado | United States | 80045 |
| 6 | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | United States | 48109 |
| 7 | Cleveland Clinic Foundation | Cleveland | Ohio | United States | 44195 |
| 8 | Ohio State University Comprehensive Cancer Center | Columbus | Ohio | United States | 43210 |
| 9 | Clackamas Radiation Oncology Center | Clackamas | Oregon | United States | 97015 |
| 10 | Providence Milwaukie Hospital | Milwaukie | Oregon | United States | 97222 |
| 11 | Providence Newberg Medical Center | Newberg | Oregon | United States | 97132 |
| 12 | Providence Willamette Falls Medical Center | Oregon City | Oregon | United States | 97045 |
| 13 | Providence Portland Medical Center | Portland | Oregon | United States | 97213 |
| 14 | Providence Saint Vincent Medical Center | Portland | Oregon | United States | 97225 |
| 15 | Oregon Health and Science University | Portland | Oregon | United States | 97239 |
| 16 | PeaceHealth Southwest Medical Center | Vancouver | Washington | United States | 98664 |
Sponsors and Collaborators
- National Cancer Institute (NCI)
- GlaxoSmithKline
- Novartis Pharmaceuticals
Investigators
- Principal Investigator: Antoni Ribas, Southwest Oncology Group
Study Documents (Full-Text)
More Information
Publications
None provided.- NCI-2013-01320
- NCI-2013-01320
- S1221
- SWOG-S1221
- S1221
- S1221
- U10CA180830
- U10CA180888
- U10CA032102
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail | 27 participants were enrolled, however 1 participant on the Dabrafenib + GSK2141795 75 mg arm and 1 participant on the Dabrafenib + Trametinib 1.5mg + GSK2141795 25mg were found to be ineligible. Furthermore, 3 participants on the Dabrafenib + GSK2141795 75 mg arm did not receive protocol treatment were not evaluable for any study endpoint. |
| Arm/Group Title | Dabrafenib + GSK2141795 50 mg | Dabrafenib + GSK2141795 75 mg | Dabrafenib + Trametinib 1.5mg + GSK2141795 25mg | Dabrafenib + Trametinib 1.5mg + GSK2141795 50mg | Dabrafenib + Trametinib 1.5mg + GSK2141795 75mg | Dabrafenib + Trametinib 2.0mg + GSK2141795 75mg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Doublet regimen cohort 1: participants were given 150 mg of dabrafenib twice daily and 50 mg of GSK2141795 once daily. | Doublet regimen cohort 2: participants were given 150 mg of dabrafenib twice daily and 75 mg of GSK2141795 once daily. | Triplet regimen cohort 1: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 25mg of GSK2141795 once daily. | Triplet regimen cohort 2: participants were given 150mg of dabrafenib twice daily, 1.5mg of trametinib and 50mg of GSK2141795 once daily. | Triplet regimen cohort 3: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 75mg of GSK2141795 once daily. | Triplet regimen cohort 4: participants were given 150 mg of dabrafenib twice daily, 2 mg of trametinib and 75 mg of GSK2141795 once daily. |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 3 | 0 | 0 | 0 | 0 | 0 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 3 | 0 | 0 | 0 | 0 | 0 |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 0 | 9 | 0 | 0 | 0 | 0 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 9 | 0 | 0 | 0 | 0 |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 0 | 0 | 4 | 0 | 0 | 0 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 4 | 0 | 0 | 0 |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 0 | 0 | 0 | 3 | 0 | 0 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 3 | 0 | 0 |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 0 | 0 | 0 | 0 | 3 | 0 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 3 | 0 |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 0 | 0 | 0 | 0 | 0 | 5 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 5 |
| Period Title: Phase 1 Doublet Regimen Cohort 1 | ||||||
| STARTED | 0 | 0 | 0 | 0 | 0 | 0 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Dabrafenib + GSK2141795 50 mg | Dabrafenib + GSK2141795 75 mg | Dabrafenib + Trametinib 1.5mg + GSK2141795 25mg | Dabrafenib + Trametinib 1.5mg + GSK2141795 50mg | Dabrafenib + Trametinib 1.5mg + GSK2141795 75mg | Dabrafenib + Trametinib 2.0mg + GSK2141795 75mg | Total |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Doublet regimen cohort 1: participants were given 150 mg of dabrafenib twice daily and 50 mg of GSK2141795 once daily. | Doublet regimen cohort 2: participants were given 150 mg of dabrafenib twice daily and 75 mg of GSK2141795 once daily | Triplet regimen cohort 1: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 25mg of GSK2141795 once daily. | Triplet regimen cohort 2: participants were given 150mg of dabrafenib twice daily, 1.5mg of trametinib and 50mg of GSK2141795 once daily | Triplet regimen cohort 3: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 75mg of GSK2141795 once daily. | Triplet regimen cohort 4: participants were given 150 mg of dabrafenib twice daily, 2 mg of trametinib and 75 mg of GSK2141795 once daily. | Total of all reporting groups |
| Overall Participants | 3 | 5 | 3 | 3 | 3 | 5 | 22 |
| Age (years) [Median (Full Range) ] | |||||||
| Median (Full Range) [years] |
60.7
|
64.4
|
63.9
|
40.1
|
56.7
|
50.4
|
58.1
|
| Sex: Female, Male (Count of Participants) | |||||||
| Female |
0
0%
|
1
20%
|
1
33.3%
|
2
66.7%
|
2
66.7%
|
2
40%
|
8
36.4%
|
| Male |
3
100%
|
4
80%
|
2
66.7%
|
1
33.3%
|
1
33.3%
|
3
60%
|
14
63.6%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||||||
| Hispanic or Latino |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Not Hispanic or Latino |
3
100%
|
5
100%
|
3
100%
|
3
100%
|
2
66.7%
|
5
100%
|
21
95.5%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
33.3%
|
0
0%
|
1
4.5%
|
| Race (NIH/OMB) (Count of Participants) | |||||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| White |
3
100%
|
5
100%
|
3
100%
|
3
100%
|
2
66.7%
|
5
100%
|
21
95.5%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
33.3%
|
0
0%
|
1
4.5%
|
| Prior BRAF inhibitor (Count of Participants) | |||||||
| Yes |
2
66.7%
|
4
80%
|
1
33.3%
|
1
33.3%
|
2
66.7%
|
3
60%
|
13
59.1%
|
| No |
1
33.3%
|
1
20%
|
2
66.7%
|
2
66.7%
|
1
33.3%
|
1
20%
|
8
36.4%
|
| Not reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
20%
|
1
4.5%
|
| Type of cancer (Count of Participants) | |||||||
| Melanoma |
2
66.7%
|
4
80%
|
2
66.7%
|
3
100%
|
3
100%
|
4
80%
|
18
81.8%
|
| Lung |
0
0%
|
1
20%
|
1
33.3%
|
0
0%
|
0
0%
|
1
20%
|
3
13.6%
|
| Thyroid |
1
33.3%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
4.5%
|
Outcome Measures
| Title | Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib. |
|---|---|
| Description | MTD was evaluated by testing increasing doses up to 75 mg once a day, given in combination with dabrafenib dosed at 150 mg twice daily. MTD reflects the highest dose that did not cause a DLT. DLTs were defined as treatment regimen related: febrile neutropenia; Grade 4 neutropenia lasting more than 7 days; Grade 4 platelet count decrease; Grade 3-4 rash, fever, or hyperglycemia > 14 days, e) Grade 3-4 non-hematologic adverse events lasting greater than 7 days. Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
| Time Frame | Every 2 weeks during days 1-56 of treatment. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Eligible, analyzable and evaluable participants that were assessed for DLT. In the Dabrafenib + GSK2141795 75 mg arm, 1 participant was ineligible, 3 participants were not analyzable, and 1 participant did not satisfy protocol-specified criteria for DLT evaluation. These patients were excluded from DLT analysis. |
| Arm/Group Title | Phase 1 Doublet Regimen |
|---|---|
| Arm/Group Description | All analyzable patients who experienced a dose limiting toxicity OR at least received GSK2141795 for 11 days in Cycle 1 and dabrafenib for 28 days in cycles 1 and 2 OR at least received GSK2141795 for 11 days in Cycle 1 and 50% of dabrafenib in Cycle 1 |
| Measure Participants | 7 |
| Number [mg] |
75
|
| Title | Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib. |
|---|---|
| Description | MTD was evaluated by testing increasing doses up to 75 mg once a day, given in combination with dabrafenib dosed at 150 mg twice daily and trametinib at either 1.5 mg or 2 mg once a day. MTD reflects the highest dose that did not cause a dose-limiting toxicity (DLT). DLTs were defined as treatment regimen related: febrile neutropenia; Grade 4 neutropenia lasting more than 7 days; Grade 4 platelet count decrease; Grade 3-4 rash, fever, or hyperglycemia > 14 days, e) Grade 3-4 non-hematologic adverse events lasting greater than 7 days. Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Note: MTD for the triplet regimen could not be determined due to the end of supply of the study drug. Number reported is the maximum dose of GSK2141795 that was assessed in combination with 150 mg Dabrafenib and 2 mg trametinib. |
| Time Frame | Every 2 weeks during days 1-56 of treatment. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Eligible and evaluable participants that were assessed for DLT. 1 participant in the Dabrafenib + Trametinib 1.5 mg + GSK2141795 25 mg was not eligible. 1 participant in the Dabrafenib + Trametinib 2.0 mg + GSK2141795 75 mg arm did not satisfy protocol-specified criteria for DLT evaluation and was thus excluded. |
| Arm/Group Title | Phase 1 Triplet Regimen |
|---|---|
| Arm/Group Description | All analyzable patients who experienced a dose limiting toxicity OR at least received GSK2141795 for 11 days in Cycle 1 and dabrafenib and trametinib for 28 days each in cycles 1 and 2 OR at least received GSK2141795 for 11 days in Cycle1 and 50% of dabrafenib and trametinib each in Cycle 1 |
| Measure Participants | 13 |
| Number [mg] |
75
|
| Title | Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses) as Assessed by RECIST Version 1.1 of the Doublet Regimen GSK2141795 + Dabrafenib at the Phase I Determined MTD. (Phase II) |
|---|---|
| Description | All measurable lesions up to a maximum of 2 lesions per organ 5 lesions in total, representative of all involved organs, were identified as target lesions at baseline. All other lesions (or sites of disease) were identified as non-target lesions. Complete Response (CR): Complete disappearance of all target and nontarget lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to < 1.0 cm. Partial Response (PR): <= 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Unconfirmed CR: One objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR: One objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR. |
| Time Frame | Disease assessments every 8 weeks for up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | Dabrafenib + GSK2141795 at MTD |
|---|---|
| Arm/Group Description | Patients who received at least one dose of protocol therapy at the Phase I determined MTD. |
| Measure Participants | 0 |
| Title | Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses) as Assessed by RECIST Version 1.1 of the Triplet Regimen GSK2141795 + Dabrafenib + Trametinib at the Phase I Determined MTD. (Phase II) |
|---|---|
| Description | All measurable lesions up to a maximum of 2 lesions per organ 5 lesions in total, representative of all involved organs, were identified as target lesions at baseline. All other lesions (or sites of disease) were identified as non-target lesions. Complete Response (CR): Complete disappearance of all target and nontarget lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to < 1.0 cm. Partial Response (PR): <= 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Unconfirmed CR: One objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR: One objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR. |
| Time Frame | Disease assessments every 8 weeks for up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | Dabrafenib + Trametinib + GSK2141795 at MTD |
|---|---|
| Arm/Group Description | Patients who received at least one dose of protocol therapy at the Phase I determined MTD. |
| Measure Participants | 0 |
| Title | Overall Survival (Phase II) of Patients Treated at the Phase I Determined MTD of Doublet Regimen |
|---|---|
| Description | Estimated with 95% confidence interval. |
| Time Frame | From date of registration to date of death due to any cause, assessed up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | GSK2141795 + Dabrafenib at the Phase I Determined MTD |
|---|---|
| Arm/Group Description | Patients who received at least 1 dose of protocol therapy at the Phase I determined MTD |
| Measure Participants | 0 |
| Title | Overall Survival (Phase II) of Patients Treated at the Phase I Determined MTD of Triplet Regimen |
|---|---|
| Description | Estimated with 95% confidence interval. |
| Time Frame | From date of registration to date of death due to any cause, assessed up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | GSK2141795 + Dabrafenib + Trametinib at Phase I Determined MTD |
|---|---|
| Arm/Group Description | Patients who received at least 1 dose of protocol therapy at the Phase I determined MTD |
| Measure Participants | 0 |
| Title | Progression-free Survival as Assessed by RECIST Version 1.1 of the Doublet Regimen at the Phase I Determined MTD (Phase II) |
|---|---|
| Description | Estimated with 95% confidence interval. |
| Time Frame | From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | Dabrafenib + GSK2141795 at Phase I Determined MTD |
|---|---|
| Arm/Group Description | Patients who received at least one dose of protocol therapy at the Phase I determined MTD. |
| Measure Participants | 0 |
| Title | Progression-free Survival as Assessed by RECIST Version 1.1 of the Triplet Regimen at the Phase I Determined MTD (Phase II) |
|---|---|
| Description | Estimated with 95% confidence interval. |
| Time Frame | From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | Dabrafenib + Trametinib + GSK2141795 at Phase I Determined MTD |
|---|---|
| Arm/Group Description | Patients who received at least one dose of protocol therapy at the phase I determined MTD |
| Measure Participants | 0 |
| Title | Toxicity Rate of MTD Graded by the NCI CTCAE Version 4.0 (Phase II) |
|---|---|
| Description | |
| Time Frame | Up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| No participants were enrolled to the Phase II portion due to the end of the supply of GSK2141795 |
| Arm/Group Title | Dabrafenib + GSK2141795 75 mg |
|---|---|
| Arm/Group Description | All participants on the Phase II triplet combination of dabrafenib, trametinib and GSK2141795 MTD . |
| Measure Participants | 0 |
| Title | Pharmacokinetic Parameters |
|---|---|
| Description | |
| Time Frame | Baseline, pre-dose and 1, 2, 4, and 8 hours on day 15, and pre-dose day 29 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Prevalence of Markers |
|---|---|
| Description | For binary markers, the prevalence will be able to be estimated and exact binomial confidence interval will be calculated. The association between these categorical markers and clinical outcomes will be explored in a preliminary manner, using Fisher's exact test to compare response and a logrank test to compare Kaplan-Meier estimates of overall survival and progression free survival between marker positive and marker negative groups. |
| Time Frame | Up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
Adverse Events
| Time Frame | 3 years | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||||
| Arm/Group Title | Dabrafenib + GSK2141795 50 mg | Dabrafenib + GSK2141795 75 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 25 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 50 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 75 mg | Dabrafenib + Trametinib 2 mg + GSK2141795 75 mg | ||||||
| Arm/Group Description | Doublet regimen cohort 1: participants were given 150 mg of dabrafenib twice daily and 50 mg of GK2141795 once daily. | Doublet regimen cohort 2: participants were given 150 mg of dabrafenib twice daily and 75 mg of GK2141795 once daily. | Triplet regimen cohort 1: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 25 mg of GK2141795 once daily. | Triplet regimen cohort 2: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 50 mg of GK2141795 once daily. | Triplet regimen cohort 3: participants were given 150 mg of dabrafenib twice daily, 1.5 mg of trametinib and 75 mg of GK2141795 once daily. | Triplet regimen cohort 4: participants were given 150 mg of dabrafenib twice daily, 2 mg of trametinib and 75 mg of GK2141795 once daily. | ||||||
All Cause Mortality |
||||||||||||
| Dabrafenib + GSK2141795 50 mg | Dabrafenib + GSK2141795 75 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 25 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 50 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 75 mg | Dabrafenib + Trametinib 2 mg + GSK2141795 75 mg | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/3 (100%) | 3/5 (60%) | 2/3 (66.7%) | 2/3 (66.7%) | 2/3 (66.7%) | 4/5 (80%) | ||||||
Serious Adverse Events |
||||||||||||
| Dabrafenib + GSK2141795 50 mg | Dabrafenib + GSK2141795 75 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 25 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 50 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 75 mg | Dabrafenib + Trametinib 2 mg + GSK2141795 75 mg | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 2/3 (66.7%) | 2/5 (40%) | 2/3 (66.7%) | 1/3 (33.3%) | 1/3 (33.3%) | 5/5 (100%) | ||||||
| Cardiac disorders | ||||||||||||
| Atrial fibrillation | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Gastrointestinal disorders | ||||||||||||
| Abdominal pain | 0/3 (0%) | 2/5 (40%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Nausea | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Small intestinal obstruction | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Upper gastrointestinal hemorrhage | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| General disorders | ||||||||||||
| Fatigue | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Fever | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 3/5 (60%) | ||||||
| General disorders and admin site conditions - Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Localized edema | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Non-cardiac chest pain | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Immune system disorders | ||||||||||||
| Allergic reaction | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Infections and infestations | ||||||||||||
| Lung infection | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Sepsis | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Urinary tract infection | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Metabolism and nutrition disorders | ||||||||||||
| Dehydration | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Hypercalcemia | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Hyperglycemia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hypokalemia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hyponatremia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Hypophosphatemia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Musculoskeletal and connective tissue disorders | ||||||||||||
| Flank pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Pain in extremity | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||||||
| Neoplasms benign, malignant and unspecified - Other | 1/3 (33.3%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 2/5 (40%) | ||||||
| Tumor pain | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Nervous system disorders | ||||||||||||
| Seizure | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Syncope | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Psychiatric disorders | ||||||||||||
| Confusion | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Skin and subcutaneous tissue disorders | ||||||||||||
| Rash maculo-papular | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Skin and subcutaneous tissue disorders - Other | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Vascular disorders | ||||||||||||
| Thromboembolic event | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
Other (Not Including Serious) Adverse Events |
||||||||||||
| Dabrafenib + GSK2141795 50 mg | Dabrafenib + GSK2141795 75 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 25 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 50 mg | Dabrafenib + Trametinib 1.5 mg + GSK2141795 75 mg | Dabrafenib + Trametinib 2 mg + GSK2141795 75 mg | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/3 (100%) | 5/5 (100%) | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) | 5/5 (100%) | ||||||
| Blood and lymphatic system disorders | ||||||||||||
| Anemia | 1/3 (33.3%) | 3/5 (60%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Febrile neutropenia | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Cardiac disorders | ||||||||||||
| Cardiac disorders-Other | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Sinus tachycardia | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Congenital, familial and genetic disorders | ||||||||||||
| Congenital, familial and genetic disorders - Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Ear and labyrinth disorders | ||||||||||||
| Ear pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Tinnitus | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Eye disorders | ||||||||||||
| Dry eye | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Eye disorders-Other | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Flashing lights | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Uveitis | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Gastrointestinal disorders | ||||||||||||
| Abdominal pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 2/3 (66.7%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Ascites | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Constipation | 1/3 (33.3%) | 0/5 (0%) | 2/3 (66.7%) | 0/3 (0%) | 0/3 (0%) | 3/5 (60%) | ||||||
| Diarrhea | 1/3 (33.3%) | 2/5 (40%) | 1/3 (33.3%) | 0/3 (0%) | 2/3 (66.7%) | 2/5 (40%) | ||||||
| Dyspepsia | 0/3 (0%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Gastroesophageal reflux disease | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Gastrointestinal disorders-Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Mucositis oral | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Nausea | 2/3 (66.7%) | 3/5 (60%) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) | 3/5 (60%) | ||||||
| Vomiting | 2/3 (66.7%) | 2/5 (40%) | 2/3 (66.7%) | 2/3 (66.7%) | 1/3 (33.3%) | 2/5 (40%) | ||||||
| General disorders | ||||||||||||
| Chills | 1/3 (33.3%) | 2/5 (40%) | 2/3 (66.7%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Edema limbs | 2/3 (66.7%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Fatigue | 3/3 (100%) | 3/5 (60%) | 3/3 (100%) | 1/3 (33.3%) | 1/3 (33.3%) | 3/5 (60%) | ||||||
| Fever | 1/3 (33.3%) | 1/5 (20%) | 2/3 (66.7%) | 2/3 (66.7%) | 1/3 (33.3%) | 2/5 (40%) | ||||||
| Flu like symptoms | 1/3 (33.3%) | 2/5 (40%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Gait disturbance | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| General disorders and admin site conditions - Other | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Irritability | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Malaise | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Non-cardiac chest pain | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Hepatobiliary disorders | ||||||||||||
| Gallbladder obstruction | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Immune system disorders | ||||||||||||
| Allergic reaction | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Infections and infestations | ||||||||||||
| Bronchial infection | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Infections and infestations-Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Lung infection | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Otitis media | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Papulopustular rash | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Pharyngitis | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Sepsis | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Sinusitis | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Soft tissue infection | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Upper respiratory infection | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Urinary tract infection | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Injury, poisoning and procedural complications | ||||||||||||
| Bruising | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Fall | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Injury, poison and procedural complications - Other | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Investigations | ||||||||||||
| Activated partial thromboplastin time prolonged | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Alanine aminotransferase increased | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 1/3 (33.3%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Alkaline phosphatase increased | 1/3 (33.3%) | 0/5 (0%) | 1/3 (33.3%) | 1/3 (33.3%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Aspartate aminotransferase increased | 1/3 (33.3%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Creatinine increased | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| INR increased | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Investigations-Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Lipase increased | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Lymphocyte count decreased | 2/3 (66.7%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Neutrophil count decreased | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 3/5 (60%) | ||||||
| Platelet count decreased | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Weight loss | 2/3 (66.7%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| White blood cell decreased | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 3/5 (60%) | ||||||
| Metabolism and nutrition disorders | ||||||||||||
| Anorexia | 2/3 (66.7%) | 3/5 (60%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Dehydration | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 2/5 (40%) | ||||||
| Hypercalcemia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hyperglycemia | 2/3 (66.7%) | 2/5 (40%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Hypernatremia | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hypoalbuminemia | 1/3 (33.3%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Hypocalcemia | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hypokalemia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Hypomagnesemia | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Hyponatremia | 1/3 (33.3%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Hypophosphatemia | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Musculoskeletal and connective tissue disorders | ||||||||||||
| Arthralgia | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Back pain | 0/3 (0%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Bone pain | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Chest wall pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Flank pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Generalized muscle weakness | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 2/5 (40%) | ||||||
| Joint effusion | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Muscle weakness upper limb | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Musculoskeletal and connective tiss disorder - Other | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Myalgia | 2/3 (66.7%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Neck pain | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Pain in extremity | 2/3 (66.7%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 2/5 (40%) | ||||||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||||||
| Neoplasms benign, malignant and unspecified - Other | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Tumor pain | 0/3 (0%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Nervous system disorders | ||||||||||||
| Dizziness | 1/3 (33.3%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Dysphasia | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Headache | 0/3 (0%) | 2/5 (40%) | 0/3 (0%) | 2/3 (66.7%) | 0/3 (0%) | 3/5 (60%) | ||||||
| Nervous system disorders-Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Peripheral sensory neuropathy | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Presyncope | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Sinus pain | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Somnolence | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Tremor | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Vasovagal reaction | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Psychiatric disorders | ||||||||||||
| Anxiety | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Confusion | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Depression | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Insomnia | 1/3 (33.3%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Psychiatric disorders-Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Renal and urinary disorders | ||||||||||||
| Hematuria | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Proteinuria | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Renal and urinary disorders-Other | 0/3 (0%) | 2/5 (40%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Urinary frequency | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Urinary incontinence | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Reproductive system and breast disorders | ||||||||||||
| Vaginal inflammation | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||||
| Allergic rhinitis | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Cough | 1/3 (33.3%) | 2/5 (40%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Dyspnea | 2/3 (66.7%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Epistaxis | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Hypoxia | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Nasal congestion | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Pleuritic pain | 2/3 (66.7%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Pneumonitis | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Postnasal drip | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Productive cough | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Resp, thoracic and mediastinal disorders - Other | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Sore throat | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Skin and subcutaneous tissue disorders | ||||||||||||
| Alopecia | 0/3 (0%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Bullous dermatitis | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Dry skin | 0/3 (0%) | 1/5 (20%) | 2/3 (66.7%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Erythema multiforme | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hyperhidrosis | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Nail discoloration | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Nail ridging | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Pain of skin | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Palmar-plantar erythrodysesthesia syndrome | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Photosensitivity | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Pruritus | 1/3 (33.3%) | 1/5 (20%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 0/5 (0%) | ||||||
| Rash acneiform | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Rash maculo-papular | 1/3 (33.3%) | 2/5 (40%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 3/5 (60%) | ||||||
| Scalp pain | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Skin and subcutaneous tissue disorders - Other | 1/3 (33.3%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Skin hypopigmentation | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Telangiectasia | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Urticaria | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Vascular disorders | ||||||||||||
| Capillary leak syndrome | 0/3 (0%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 2/5 (40%) | ||||||
| Flushing | 0/3 (0%) | 1/5 (20%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Hypertension | 0/3 (0%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) | 1/5 (20%) | ||||||
| Hypotension | 1/3 (33.3%) | 0/5 (0%) | 1/3 (33.3%) | 0/3 (0%) | 1/3 (33.3%) | 1/5 (20%) | ||||||
| Thromboembolic event | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
| Vascular disorders-Other | 1/3 (33.3%) | 0/5 (0%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 0/5 (0%) | ||||||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Melanoma Statistician |
|---|---|
| Organization | SWOG |
| Phone | 2066674623 |
| jmoon@fredhutch.org |
- NCI-2013-01320
- NCI-2013-01320
- S1221
- SWOG-S1221
- S1221
- S1221
- U10CA180830
- U10CA180888
- U10CA032102